-
While women have several options when it comes to birth control, men are limited to condoms and vasectomies. Researchers around the globe are focusing efforts to expand those choices, including hormonal injections, gels, and implants.
-
Do you still recommend that women use backup contraception when prescribed antibiotics during oral contraceptive use? If you do, it's time to check your approach, according to information presented at the Contraceptive Technology conference.
-
Despite intense screening in the past decade, higher rates of cervical cancer persist in Hispanic women.1 How can you reach these women with the information they need for prevention and detection?
-
-
Has the telephone been ringing in your office with questions from patients who are concerned about using oral contraceptives in light of media reports questioning the Pill's safety? If so, you are not alone. What are you doing to help women place such news in proper context?
-
It's time to increase chlamydia screening in your clinic. Results of a new study show that, despite current screening recommendations, more than 2 million people are infected with chlamydia in the United States.
-
The next patient in your exam room is a 35-year-old mother of three. When you talk with her about her risks for cancer, she tells you they are low, because no one in her family has had the disease. What is your next step?
-
Help women discuss HPV, cervical cancer, and Pap tests with health care providers, with a new brochure, "Ask How You Can Prevent Cervical Cancer."
-
Prompt, accurate assessment of the severity of injury and early initiation of appropriate critical care — including adequate oxygenation, ventilation and correction of hypotension — is of crucial importance in preventing deaths in children with severe trauma. This article reviews the critical aspects of airway assessment and management in the pediatric trauma patient.
-
FDA warnings for existing drugs dominate pharmaceutical news this month. These warnings represent a new push by the FDA to regulate existing drugs for safety after they have been approved for marketing. It also comes at a time when the FDA is cleaning up its advisory committee processes, especially with regard to limiting potential conflict of interest by advisory committee members.
